Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Accumulated Expenses (2016 - 2025)

Coherus Oncology's Accumulated Expenses history spans 12 years, with the latest figure at $13.1 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 78.51% year-over-year to $13.1 million; the TTM value through Sep 2025 reached $13.1 million, down 78.51%, while the annual FY2024 figure was $60.3 million, 180.14% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $13.1 million at Coherus Oncology, down from $14.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $115.7 million in Q1 2024 and bottomed at $3.6 million in Q2 2024.
  • The 5-year median for Accumulated Expenses is $22.1 million (2022), against an average of $33.5 million.
  • The largest YoY upside for Accumulated Expenses was 295.73% in 2025 against a maximum downside of 82.76% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $48.1 million in 2021, then crashed by 53.02% to $22.6 million in 2022, then fell by 4.82% to $21.5 million in 2023, then skyrocketed by 180.14% to $60.3 million in 2024, then crashed by 78.27% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Accumulated Expenses are $13.1 million (Q3 2025), $14.2 million (Q2 2025), and $20.0 million (Q1 2025).